Tas-120-101 nct02052778

Author: wdyy

August undefined, 2024

WebTPU-TAS-120-101: National Competent Authority: UK - MHRA: Clinical Trial Type: EEA CTA: Trial Status: ... NCT02052778: A.5.4: Other Identifiers: Name: IND Number: Number: … WebJul 1, 2024 · TAS-120 is a highly potent and selective, covalently bound small-molecule inhibitor of FGFR1-4. This Phase I dose-escalation study investigated the safety, dose …

Futibatinib Earns Breakthrough Therapy Designation for FGFR2 ...

WebLytgobi is developed and commercialized by Taiho Oncology. The FDA approval of Lytgobi comes as a result of the Phase I/II, open-label, single-arm TAS-120-101 (NCT02052778) … WebSep 30, 2024 · Efficacy was evaluated in TAS-120-101 (NCT02052778), a multicenter, open-label, single-arm trial that enrolled 103 patients with previously treated, unresectable, … case ih service manual

Australian Clinical Trials Australian Clinical Trials

Web544P - Phase I study of the irreversible FGFR inhibitor (i) futibatinib (FBN; TAS-120) in Japanese patients (pts) with ... Taiho Pharmeceutical Co. Ltd, 101-0047 - Tokyo/JP; 7 … WebNov 3, 2024 · The regulatory decision was based on findings from the phase 2 FOENIX*-CCA2 trial (TAS-120-101; NCT02052778), in which the agent elicited an overall response … WebSep 30, 2024 · Efficacy was evaluated in TAS-120-101 (NCT02052778), a multicenter, open-label, single-arm trial that enrolled 103 patients with previously treated, unresectable, … case ih slogans

Abstract CT121: Phase I dose-escalation study of TAS-120, a …

Tas-120-101 nct02052778

A Study of TAS-120 in Patients With Advanced Solid …

WebOct 3, 2024 · The approval of futibatinib was based on data from the multicenter, open-label, single-arm, phase 2 FOENIX*-CCA2 trial (TAS-120-101; NCT02052778) in 103 patients … WebNCT ID: NCT02052778. Sponsor Protocol Number: TPU-TAS-120-101. About this study. The purpose of this study is to determine the safety of TAS-120 and determine the most …

Did you know?

WebSep 30, 2024 · The FDA has granted accelerate approval to futibatinib (Lytgobi) for patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma … WebFOENIX-101 (ClinicalTrials.gov, NCT02052778). Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors

WebFeb 1, 2024 · FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. February 2024; ... Methods: FOENIX-CCA2 (NCT02052778), ... WebNov 17, 2024 · Efficacy was evaluated in TAS-120-101 (NCT02052778), a multicenter, open-label, single-arm trial that enrolled 103 patients with previously treated, unresectable, …

WebFeb 1, 2024 · FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. February 2024; ... Methods: … WebFeb 13, 2024 · The FDA approval of Lytgobi comes as a result of the Phase I/II, open-label, single-arm TAS-120-101 (NCT02052778) clinical trial which evaluated the use of Lytgobi …

WebThis is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120). The purpose of the study is to evaluate the …

WebOrg Study ID: TPU-TAS-120-101; Secondary ID: 2013-004810-16; NTC ID: NCT02052778; Sponsor: Taiho Oncology, Inc. BRIEF SUMMARY This is an open-label, nonrandomized, … case ih stock price todayWeb¶ A total of 101 patients (98%) received previous systemic therapy for unresectable or metastatic intrahepatic cholangiocarcinoma. 10.1056/NEJMoa2206834-t2 Table 2. case ih snowmobileWebSep 30, 2024 · Efficacy was evaluated in TAS-120-101 (NCT02052778), a multicenter, open-label, single-arm trial that enrolled 103 patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring a FGFR2 gene fusion or other rearrangement. The presence of FGFR2 fusions or other rearrangements was … case ih snoopyWebJan 23, 2014 · Clinical Trial NCT02052778; A Study of TAS-120 in Patients With Advanced Solid Tumors January 5, 2024 updated by: Taiho Oncology, Inc. ... TPU-TAS-120-101 … case ih stock priceWebOct 3, 2024 · Efficacy was evaluated in TAS-120-101 (NCT02052778), a multicenter, open-label, single-arm trial that enrolled 103 patients with previously treated, unresectable, … case ih staplesWebSep 30, 2024 · The regulatory decision was supported by data from the multicenter, open-label, single-arm, phase 2 FOENIX*-CCA2 trial (TAS-120-101; NCT02052778), which showed that among 103 patients, futibatinib ... case ih stockWebFeb 1, 2024 · Most FGFR inhibitors being evaluated in the clinic are reversible ATP-competitive inhibitors (), and the activity of these agents is mainly seen in select tumor … case ih stock symbol